OrbiMed

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly for patients with mTOR pathway driver alterations, such as those involving the TSC1 or TSC2 genes. Aadi's primary aim is to create transformational therapies for patients with specific cancer types, including the ultra-rare perivascular epithelioid cell tumor (PEComa). The company addresses challenges faced by existing mTOR inhibitors, including issues related to pharmacology, drug delivery, safety, and targeting. Founded in 2011, Aadi Bioscience has positioned itself to innovate in the treatment of oncology and cardiovascular diseases.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

Verdiva Bio is a biopharmaceutical company specializing in the development of innovative therapies for patients with obesity and cardiometabolic disorders. The company focuses on creating more patient-friendly treatment options by targeting gut-brain biology, with a pipeline centered around multiple amylin molecules. This approach aims to enhance efficacy, improve tolerability, and facilitate healthier weight loss for individuals facing these health challenges.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It is dedicated to discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. The company employs a proprietary discovery and development engine to create highly selective small molecules that modulate immune responses related to these conditions. RAPT has advanced two notable drug candidates: FLX475, which targets the inhibition of immunosuppressive regulatory T cells in tumors, and RPT193, which selectively inhibits type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short timeframe since the company's inception. Additionally, RAPT is exploring several other targets in the discovery phase, including general control nonderepressible 2 and hematopoietic progenitor kinase 1.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly for patients with mTOR pathway driver alterations, such as those involving the TSC1 or TSC2 genes. Aadi's primary aim is to create transformational therapies for patients with specific cancer types, including the ultra-rare perivascular epithelioid cell tumor (PEComa). The company addresses challenges faced by existing mTOR inhibitors, including issues related to pharmacology, drug delivery, safety, and targeting. Founded in 2011, Aadi Bioscience has positioned itself to innovate in the treatment of oncology and cardiovascular diseases.

SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics aimed at treating acute and chronic pain. The company specializes in creating products that address the limitations of existing pain management therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Its lead therapeutic candidates are selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is essential for the generation and conduction of pain signals. By targeting this specific channel, SiteOne Therapeutics aims to provide more effective and safer pain relief options for healthcare professionals and their patients, particularly in the treatment of neuropathic pain.

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

Lomond Therapeutics is a pharmaceutical firm that discovers and develops small molecule inhibitors that target escape variants in hematologic malignancies.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics aimed at addressing significant and unmet needs in central nervous system disorders. By leveraging precision medicine, Leal Therapeutics seeks to provide effective treatment options for patients suffering from various neurological conditions. The company's commitment to advancing therapeutic solutions is reflected in its dedication to improving patient outcomes through targeted interventions.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Poxel is a biopharmaceutical company based in Lyon, France, focused on developing innovative drugs for metabolic diseases, with a primary emphasis on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel's lead product is Imeglimin, an oral anti-diabetic candidate in Phase III clinical development that targets key organs affected by diabetes, such as the pancreas, liver, and muscles. The company is also advancing PXL770, an adenosine monophosphate-activated protein kinase enzyme in Phase IIa clinical trials for treating chronic metabolic diseases like NASH. Additionally, Poxel has licensing agreements for PXL007 (EYP001), an FXR agonist in Phase I study for hepatitis B and NASH, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I clinical trials for NASH.

Scorpion Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on advancing precision oncology for cancer treatment. Founded in 2020, the company specializes in developing targeted small-molecule drugs that address validated cancer targets, as well as previously undruggable and novel targets. Scorpion Therapeutics utilizes an integrated approach that combines target discovery, medicinal chemistry, and translational medicine to create a diverse pipeline of optimized compounds. By leveraging its precision medicine platform, the company aims to enhance the efficacy of cancer therapies and expand treatment options for patients, ultimately striving to overcome the limitations of existing cancer treatments.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, specializing in the development of immuno-oncology therapies. The company focuses on creating first-in-class agents that modulate the immune system to treat cancer and other diseases. Its lead product candidate, Ciforadenant (CPI-444), is an oral small molecule antagonist of the A2A receptor currently undergoing Phase Ib/2 clinical trials. Additionally, Corvus is developing CPI-006, an anti-CD73 monoclonal antibody in Phase I/Ib trials aimed at inhibiting adenosine production and stimulating immune cells, as well as a Phase I trial for COVID-19. Another candidate, CPI-818, is a small molecule inhibitor targeting interleukin-2-inducible T-cell kinase, also in Phase I/Ib trials. The company has established a strategic collaboration with Angel Pharmaceuticals to further advance its pipeline of investigational medicines. Founded in 2014, Corvus Pharmaceuticals aims to contribute significantly to the field of immunotherapy and improve patient outcomes in various diseases.

Alterome Therapeutics is a biotechnology company focused on precision oncology, specializing in the development of alteration-specific therapeutics aimed at treating cancer. By targeting high-value and validated oncogenic drivers, Alterome seeks to create innovative biopharmaceutical therapies that offer hope to individuals affected by cancer. The company's approach is centered on discovering and developing precise treatments that cater to the unique genetic alterations present in different cancer types, thereby enhancing the effectiveness of cancer therapies for healthcare providers and patients alike.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to treat aging and age-related diseases. The company utilizes a proprietary systems biology and artificial intelligence platform to identify significant drug targets that influence aging, leveraging extensive datasets to uncover the molecular drivers of age-related pathologies. Among its key offerings is BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor that activates HIF-1 target genes involved in various biological processes, including tissue regeneration and vascular remodeling. Another notable product is BGE-175, an orally administered inhibitor targeting the prostaglandin D2 DP1 signaling pathway, which is linked to an increased risk of mortality and infections, including those associated with immune aging. Founded in 2015 and headquartered in Richmond, California, BioAge Labs is dedicated to harnessing the biology of human aging to create innovative therapies for metabolic and age-related diseases.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming advanced research into innovative cancer treatments. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company focuses on accelerating the development of oncology medications to provide help and hope to cancer patients globally. OnCusp Therapeutics specializes in translating preclinical drug candidates into clinical proof-of-concept stages, aiming to swiftly advance these assets into early global clinical development.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

Forward Therapeutics is a biopharmaceutical company focused on developing innovative oral small molecule therapies to treat chronic inflammatory disorders. The company's platform, driven by leading scientific expertise, enables the discovery and development of advanced treatments that aim to significantly improve patient outcomes and address unmet medical needs in this field.

Terremoto Biosciences is a biotechnology company focused on the development and discovery of small-molecule medicines through innovative drug delivery systems. By utilizing lysine-based covalency, the company aims to optimize clinical profiles and enhance therapeutic benefits for various diseases. Terremoto's platform is designed to improve existing medications while also facilitating the creation of new therapies aimed at addressing critical healthcare challenges. Through its research and technology, Terremoto Biosciences strives to provide effective solutions for the treatment of devastating diseases, contributing to advancements in the healthcare sector.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify rare diseases that share common biological mechanisms, allowing it to create novel therapeutics capable of treating multiple conditions with a single treatment. This approach not only enhances the potential for effective solutions but also provides pharmaceutical companies with opportunities to address several rare diseases simultaneously. By targeting a diverse array of conditions, Star Therapeutics strives to significantly improve the lives of millions of patients affected by these challenging health issues.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Aer Therapeutics is a biopharmaceutical company focused on developing innovative treatments for lung diseases characterized by excess mucus and mucus plugs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to address significant unmet needs in these respiratory conditions by advancing the treatment paradigm for mucus-mediated lung diseases.

Congruence Therapeutics is a biotechnology company focused on developing pharmacological stabilizers for treating rare diseases. The company leverages computational and experimental drug discovery methods, along with structural bioinformatics, computational chemistry, and machine learning, to create an in silico platform. This platform enables the design of novel small molecules targeted at diseases caused by protein misfolding.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company aims to address unmet medical needs by identifying, developing, and commercializing differentiated medicines. ArriVent is advancing its lead development candidate, furmonertinib, alongside a pipeline of novel therapeutics, including next-generation antibody drug conjugates. The company's efforts are primarily centered on solid tumors, leveraging the team's extensive experience in drug development to enhance the potential of its therapeutic candidates from initial development through to approval and commercialization.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Alterome Therapeutics is a biotechnology company focused on precision oncology, specializing in the development of alteration-specific therapeutics aimed at treating cancer. By targeting high-value and validated oncogenic drivers, Alterome seeks to create innovative biopharmaceutical therapies that offer hope to individuals affected by cancer. The company's approach is centered on discovering and developing precise treatments that cater to the unique genetic alterations present in different cancer types, thereby enhancing the effectiveness of cancer therapies for healthcare providers and patients alike.

PIC Therapeutics, Inc. is a biotechnology company dedicated to advancing cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and headquartered in Boston, Massachusetts, the company develops precision-based therapeutics that target the master switch of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This innovative approach has the potential to simultaneously address multiple oncogenic drivers, paving the way for a new generation of cancer therapies that could significantly enhance patient outcomes.

Insmed Incorporated is a global biopharmaceutical company dedicated to improving the lives of patients with serious and rare diseases. Its flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the United States for treating Mycobacterium avium complex (MAC) lung disease, targeting adult patients who have limited or no alternative treatment options. MAC lung disease is a rare and potentially fatal infection that can lead to significant lung damage. In addition to ARIKAYCE, Insmed's clinical pipeline features Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which shows promise for treating non-cystic fibrosis bronchiectasis and other inflammatory conditions. Another candidate in development is INS1009, an inhaled formulation of a treprostinil prodrug aimed at addressing rare pulmonary disorders, including pulmonary arterial hypertension.

Treeline Biosciences is a biotechnology company founded in 2021 and based in Stamford, Connecticut. It focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. The company employs a comprehensive drug discovery platform that integrates mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science. This multidisciplinary approach is designed to support the development of innovative therapies that can significantly improve patient outcomes in oncology and beyond.

Terremoto Biosciences is a biotechnology company focused on the development and discovery of small-molecule medicines through innovative drug delivery systems. By utilizing lysine-based covalency, the company aims to optimize clinical profiles and enhance therapeutic benefits for various diseases. Terremoto's platform is designed to improve existing medications while also facilitating the creation of new therapies aimed at addressing critical healthcare challenges. Through its research and technology, Terremoto Biosciences strives to provide effective solutions for the treatment of devastating diseases, contributing to advancements in the healthcare sector.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify rare diseases that share common biological mechanisms, allowing it to create novel therapeutics capable of treating multiple conditions with a single treatment. This approach not only enhances the potential for effective solutions but also provides pharmaceutical companies with opportunities to address several rare diseases simultaneously. By targeting a diverse array of conditions, Star Therapeutics strives to significantly improve the lives of millions of patients affected by these challenging health issues.

Electra Therapeutics is a clinical stage biotechnology company focused on developing therapies aimed at treating immunological diseases and cancer. The company specializes in targeting signal regulatory proteins (SIRP) to deplete pathological immune cells. Its lead product candidate, ELA026, is a monoclonal antibody currently in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no existing approved treatments. In addition to ELA026, Electra has two preclinical programs under development, highlighting its commitment to addressing unmet medical needs in the field of immunology and oncology.

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company aims to address unmet medical needs by identifying, developing, and commercializing differentiated medicines. ArriVent is advancing its lead development candidate, furmonertinib, alongside a pipeline of novel therapeutics, including next-generation antibody drug conjugates. The company's efforts are primarily centered on solid tumors, leveraging the team's extensive experience in drug development to enhance the potential of its therapeutic candidates from initial development through to approval and commercialization.

Congruence Therapeutics is a biotechnology company focused on developing pharmacological stabilizers for treating rare diseases. The company leverages computational and experimental drug discovery methods, along with structural bioinformatics, computational chemistry, and machine learning, to create an in silico platform. This platform enables the design of novel small molecules targeted at diseases caused by protein misfolding.

HanBio Therapeutics is a biotechnology company committed to researching and developing next generation transformative medicines.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Alterome Therapeutics is a biotechnology company focused on precision oncology, specializing in the development of alteration-specific therapeutics aimed at treating cancer. By targeting high-value and validated oncogenic drivers, Alterome seeks to create innovative biopharmaceutical therapies that offer hope to individuals affected by cancer. The company's approach is centered on discovering and developing precise treatments that cater to the unique genetic alterations present in different cancer types, thereby enhancing the effectiveness of cancer therapies for healthcare providers and patients alike.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics aimed at addressing significant and unmet needs in central nervous system disorders. By leveraging precision medicine, Leal Therapeutics seeks to provide effective treatment options for patients suffering from various neurological conditions. The company's commitment to advancing therapeutic solutions is reflected in its dedication to improving patient outcomes through targeted interventions.

LifeCell International, established in 2004 and based in Chennai, is a private stem cell bank that introduced umbilical cord stem cell banking to India. The company has evolved into a comprehensive provider of stem cell solutions, offering a wide range of services that include multi-service stem cell banking, research and development, clinical trials, and stem cell therapies. With over 100 service centers across India and the Gulf Cooperation Council (GCC) countries, LifeCell aims to enhance health outcomes for future generations. Its offerings extend to menstrual stem cell banking and point-of-care therapies for orthopedic and vascular conditions, helping parents safeguard their newborns' health and reduce potential disease burdens.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focusing on the creation and commercialization of human tissue-based products for regenerative medicine and vascular surgery. Established in 2004, the company specializes in developing acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to prevent rejection. These engineered tissues are designed for use as vascular grafts, providing solutions for patients requiring vascular repair or replacement. Humacyte aims to deliver universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while advancing the field of medicine.

XinThera is a drug discovery company dedicated to developing precision medicines for the treatment of cancer and immunologic diseases. The company utilizes advanced computational chemistry technologies to design small molecule therapies aimed at well-validated targets that are often considered challenging in oncology and immunology. By focusing on these promising targets, XinThera strives to provide effective drug therapies that can address unmet medical needs for patients suffering from these conditions.

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company aims to address unmet medical needs by identifying, developing, and commercializing differentiated medicines. ArriVent is advancing its lead development candidate, furmonertinib, alongside a pipeline of novel therapeutics, including next-generation antibody drug conjugates. The company's efforts are primarily centered on solid tumors, leveraging the team's extensive experience in drug development to enhance the potential of its therapeutic candidates from initial development through to approval and commercialization.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Nautilus Biotechnology Inc. is a development stage life sciences company focused on advancing proteomics to enhance therapeutic development and medical diagnostics. The company aims to create a platform technology that quantifies and unlocks the complexity of the human proteome, ultimately facilitating personalized and predictive medicine. Nautilus has developed a prototype of its innovative single-molecule instrument, the Proteomic Analysis System, which is designed to address challenges in protein analysis that have previously hindered progress in the field. The diverse expertise of its team, which includes professionals from various scientific disciplines such as protein chemistry, molecular biology, and bioinformatics, positions Nautilus to significantly impact drug development and improve human health management.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Gennao Bio is a privately held company focused on developing innovative targeted nucleic acid therapeutics, primarily aimed at treating oncology and rare monogenic skeletal muscle diseases. The company utilizes its proprietary gene monoclonal antibody (GMAB) platform technology, which features a novel, cell-penetrating antibody that facilitates the non-covalent binding and delivery of various nucleic acid payloads to specific cells. This non-viral delivery system stands out from traditional gene therapy methods by allowing for multiple types of nucleic acids, enabling repeat dosing, and employing established manufacturing processes. Gennao Bio's approach aims to address significant unmet medical needs and improve patient outcomes in the relevant therapeutic areas.

Treeline Biosciences is a biotechnology company founded in 2021 and based in Stamford, Connecticut. It focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. The company employs a comprehensive drug discovery platform that integrates mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science. This multidisciplinary approach is designed to support the development of innovative therapies that can significantly improve patient outcomes in oncology and beyond.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapies utilizing engineered CRISPR technologies to address genetic disorders. Founded in 2018 and based in Berkeley, California, Scribe Therapeutics is known for its proprietary X-Editing (XE) molecules, which are advanced CRISPR enzymes designed to enhance efficacy, specificity, and deliverability compared to existing genome editing methods. The company's platform aims to overcome the limitations of current technologies by creating custom-engineered enzymes and delivery systems that facilitate precise genetic modifications. Scribe Therapeutics is committed to establishing CRISPR-based therapies as a new standard of clinical care, with the potential to significantly impact the treatment landscape for a variety of diseases, including those related to immuno-oncology, degenerative disorders, and enzyme replacement therapy.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that focuses on targeted DNA integration to address severe genetic diseases. The firm employs advanced technology to enable the precise insertion of genetic sequences, effectively correcting mutations, replacing malfunctioning genes, and introducing therapeutic genetic materials into specific regions of the genome. By harnessing high-efficiency targeted gene integration, Graphite Bio aims to develop novel therapies that could potentially cure a wide array of serious and life-threatening conditions. Formerly known as Integral Medicines, Inc., the company rebranded in August 2020 and has operated since its incorporation in 2019. Graphite Bio is committed to the pioneering of a precision gene editing approach designed to fulfill the medical challenge of accurately "finding and replacing" genes.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Visen Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for endocrine diseases, addressing significant unmet medical needs in China. The company emphasizes patient-centric care, aiming to provide first-in-class or best-in-class treatments for both common and rare endocrine disorders affecting adults and children. With a team of experienced professionals from multinational pharmaceutical backgrounds, Visen leverages advanced technologies and resources to enhance its operations. The company has established a strong presence in the Chinese market, with offices in Shanghai, Beijing, Hong Kong, and Taipei, as well as a research and manufacturing site in Suzhou. This strategic setup aims to accelerate the availability of advanced treatment solutions for endocrine patients in China.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

Scorpion Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on advancing precision oncology for cancer treatment. Founded in 2020, the company specializes in developing targeted small-molecule drugs that address validated cancer targets, as well as previously undruggable and novel targets. Scorpion Therapeutics utilizes an integrated approach that combines target discovery, medicinal chemistry, and translational medicine to create a diverse pipeline of optimized compounds. By leveraging its precision medicine platform, the company aims to enhance the efficacy of cancer therapies and expand treatment options for patients, ultimately striving to overcome the limitations of existing cancer treatments.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing innovative small molecule therapies to enhance patient outcomes. Established in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a unique discovery process that leverages clinically validated biological targets alongside advanced chemistry. This methodology aims to overcome the limitations of current therapies by creating potentially first-in-class treatments that address critical challenges such as tolerability, combinability, resistance, and disease progression, particularly in cases involving brain metastases. Enliven's product pipeline includes ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and act against various HER2 variants.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.

Prothelia is a private biotech company based in the United States, established in 2007. The company focuses on the research and development of therapeutic proteins aimed at treating muscular dystrophy and addressing human protein replacement deficiencies. Its lead program targets congenital muscular dystrophy type 1A, a rare condition that affects around 4,000 patients. Prothelia's innovative approach seeks to enhance treatment options for individuals suffering from muscular dystrophy, thereby contributing to advancements in biopharmaceutical therapies.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

AbCellera is a biotechnology company specializing in antibody discovery and development. It uses an integrated platform combining proprietary hardware, software, tools, and advanced data science to efficiently identify and develop optimal antibodies for clinical use. The company partners with both emerging biotechs and established pharmaceutical companies, leveraging its expertise to accelerate the drug development process and improve patient outcomes.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

AbCellera is a biotechnology company specializing in antibody discovery and development. It uses an integrated platform combining proprietary hardware, software, tools, and advanced data science to efficiently identify and develop optimal antibodies for clinical use. The company partners with both emerging biotechs and established pharmaceutical companies, leveraging its expertise to accelerate the drug development process and improve patient outcomes.

Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.